Lyrica (pregabalin) can be habit-forming. The U.S. government classifies it as a Schedule V controlled substance, the lowest category of controlled drugs, meaning it has a recognized potential for abuse and dependence, though less so than most other controlled medications. About 4% of patients in clinical trials reported feeling euphoria while taking it, compared to 1% on placebo, and in certain patient groups that rate climbed as high as 12%.
The risk isn’t the same for everyone. Your personal history with substances plays a major role in how likely Lyrica is to become a problem.
How Lyrica Affects the Brain’s Reward System
Lyrica was originally thought to have little interaction with the parts of the brain involved in addiction. Its main job is to calm overactive nerve signals by binding to calcium channels, which is why it works for nerve pain, seizures, and anxiety. But research has shown the picture is more complicated.
Animal studies have found that pregabalin increases dopamine release in the nucleus accumbens, the same brain region that lights up with opioids, cocaine, and other addictive drugs. Dopamine activity in this area drives the feeling of reward and the motivation to repeat a behavior. When researchers blocked dopamine receptors in that region, the rewarding effects of pregabalin disappeared entirely. This confirms that Lyrica does engage the brain’s reward circuitry, even though it wasn’t designed to.
Lyrica also has mild activity on the brain’s calming system (GABA pathways), which may contribute to the relaxation and euphoria some people experience. In a study of 15 recreational drug users, a single high dose of Lyrica produced feelings of being “high” and a “good drug effect” at levels comparable to a high dose of diazepam (Valium).
Who Is Most at Risk
The single biggest risk factor is a current or past substance use disorder. A systematic review of the evidence found that the vast majority of people who developed problems with pregabalin were already dependent on other substances, most commonly opioids or sedatives. People who use multiple substances and those with psychiatric conditions are also at elevated risk. A study at a de-addiction center found that about 35% of patients misusing pregabalin had a family history of substance use as well.
For people without any history of substance misuse, the addictive pull of Lyrica appears to be quite weak. That same systematic review found only four documented cases of behavioral dependence in patients with no prior abuse history, and concluded there was no convincing evidence of “vigorous addictive power” in the general population. This is a meaningful distinction: Lyrica’s habit-forming potential is real but concentrated in a specific, identifiable group of people.
Tolerance and Dose Escalation
Tolerance means your body adapts to a drug so that the same dose produces less effect over time. This can happen with Lyrica, particularly in people who are taking it for its euphoric or calming effects rather than for a medical condition. Case reports describe patients who started at a normal prescribed dose and gradually escalated to extreme amounts. One published case documented a patient whose use became regular over several months, eventually reaching 25 to 30 capsules per day.
Tolerance-driven dose escalation is one of the clearest warning signs that a drug is becoming habit-forming for a particular individual. If you notice that your prescribed dose of Lyrica feels less effective and you feel compelled to take more, that pattern deserves attention.
Withdrawal Symptoms
Physical dependence on Lyrica can develop even in people taking it exactly as prescribed, and it becomes apparent when the drug is stopped. The FDA label notes that patients who abruptly discontinued Lyrica reported insomnia, nausea, headache, and diarrhea. Post-marketing reports have added anxiety and heavy sweating to that list.
Case reports paint a broader picture. Patients withdrawing from regular, prescribed doses have experienced:
- Anxiety, restlessness, and insomnia
- Palpitations, sweating, and rapid heart rate
- Headache, shortness of breath, and loss of appetite
- Tremors and psychomotor agitation
- In rare, severe cases: hallucinations, seizures, delirium, and suicidal thoughts
Withdrawal symptoms typically begin within one to four days after stopping the drug, though onset has been reported anywhere from 24 hours to a full week later. In documented cases, symptoms improved quickly once pregabalin was restarted, often resolving within a couple of days. This rapid improvement confirms the symptoms are directly tied to the drug’s absence rather than a return of the underlying condition.
How to Stop Lyrica Safely
Because of the withdrawal risk, Lyrica should not be stopped abruptly. Clinical guidelines recommend tapering the dose gradually over at least one week. For people with seizure disorders, a slow taper is especially important because sudden discontinuation can trigger new or worsening seizures.
There is no single tapering schedule that works for everyone. The right pace depends on your current dose, how long you’ve been taking it, and whether you experience withdrawal symptoms during the taper. A slower reduction over several weeks is common for people who have been on higher doses or have taken the drug for a long time.
What the Scheduling Means for You
The DEA placed pregabalin in Schedule V in 2005 based on three findings: it has a low potential for abuse relative to Schedule IV drugs (which include benzodiazepines like Valium and Xanax), it has accepted medical uses, and its abuse may lead to limited physical or psychological dependence compared to those same drugs. Schedule V is the least restrictive controlled category, shared with certain cough medicines containing small amounts of codeine.
In practical terms, this means your pharmacist tracks Lyrica prescriptions, refills may require closer monitoring than unscheduled medications, and prescribers are advised to evaluate your substance use history before writing a prescription. The FDA label specifically instructs clinicians to watch for signs of tolerance, dose escalation, and drug-seeking behavior in patients taking Lyrica.
Lyrica is less habit-forming than opioids, benzodiazepines, or stimulants by a wide margin. But “less addictive” is not the same as “not addictive.” If you have a history of substance use problems, the risk is real and worth discussing openly before starting or continuing the medication.